Principal Securities’s PTC Therapeutics PTCT Stock Holding History

Principal Securities’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-814	Closed	-$50K	–	2973
2025 Q3	$50K	Buy	+814	New	+$42.4K	﹤0.01%	1946

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Principal Securities's PTCT Position: Q4 2025 in Review

Principal Securities sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 814 shares — an estimated $50K sold.

Principal Securities first reported a position in PTCT in Q3 2025 and held it in 1 quarter. The position peaked at $50K in Q3 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

Principal Securities reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 814 PTC Therapeutics shares in Q4 2025, an estimated $50K.
Principal Securities first reported a position in PTC Therapeutics in Q3 2025 and held it in 1 quarter.
Principal Securities's PTC Therapeutics position peaked at $50K in Q3 2025.
352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.